469 related articles for article (PubMed ID: 30648932)
21. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
Azuma M; Oishi K; Akeda Y; Morino S; Motoki Y; Hanibuchi M; Nishioka Y
Vaccine; 2023 Jan; 41(5):1042-1049. PubMed ID: 36593171
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.
Shiramoto M; Hanada R; Juergens C; Shoji Y; Yoshida M; Ballan B; Cooper D; Gruber WC; Scott DA; Schmoele-Thoma B
Hum Vaccin Immunother; 2015; 11(9):2198-206. PubMed ID: 26176163
[TBL] [Abstract][Full Text] [Related]
24. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
[TBL] [Abstract][Full Text] [Related]
25. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
26. Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
Lee S; Kim HW; Lee JH; Kim KH
Vaccine; 2017 Sep; 35(37):4960-4965. PubMed ID: 28778614
[TBL] [Abstract][Full Text] [Related]
27. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
28. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
Haranaka M; Young Song J; Huang KC; de Solom R; Yamaji M; McElwee K; Kline M; Aizawa M; Peng Y; Scully I; Kogawara O; Gruber WC; Scott DA; Watson W
Vaccine; 2024 Feb; 42(5):1071-1077. PubMed ID: 38267330
[TBL] [Abstract][Full Text] [Related]
29. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
30. Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico.
Tinoco JC; Juergens C; Ruiz Palacios GM; Vazquez-Narvaez J; Enkerlin-Pauwells HL; Sundaraiyer V; Pathirana S; Kalinina E; Gruber WC; Scott DA; Schmoele-Thoma B
Clin Vaccine Immunol; 2015 Feb; 22(2):185-92. PubMed ID: 25499011
[TBL] [Abstract][Full Text] [Related]
31. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L;
AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067
[TBL] [Abstract][Full Text] [Related]
32. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
33. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
Chichili GR; Smulders R; Santos V; Cywin B; Kovanda L; Van Sant C; Malinoski F; Sebastian S; Siber G; Malley R
Vaccine; 2022 Jul; 40(31):4190-4198. PubMed ID: 35690500
[TBL] [Abstract][Full Text] [Related]
34. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.
Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Booy R
Vaccine; 2016 Nov; 34(48):5929-5937. PubMed ID: 27780630
[TBL] [Abstract][Full Text] [Related]
35. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.
Papadatou I; Lagousi T; Kattamis A; Spoulou V
Ann Hematol; 2019 Mar; 98(3):775-779. PubMed ID: 30683996
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
[TBL] [Abstract][Full Text] [Related]
37. Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.
Sterrett S; Peng BJ; Burton RL; LaFon DC; Westfall AO; Singh S; Pride M; Anderson AS; Ippolito GC; Schroeder HW; Nahm MH; Krishna Prasad A; Goepfert P; Bansal A
Vaccine; 2020 Feb; 38(7):1778-1786. PubMed ID: 31911030
[TBL] [Abstract][Full Text] [Related]
38. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
[TBL] [Abstract][Full Text] [Related]
39. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
[No Abstract] [Full Text] [Related]
40. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.
Eriksson M; Käyhty H; Saha H; Lahdenkari M; Koskinen P; Mäkisalo H; Anttila VJ
Transpl Infect Dis; 2020 Aug; 22(4):e13343. PubMed ID: 32473046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
